Filtered By:
Condition: Pain
Education: Learning

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 161 results found since Jan 2013.

Automatic Classification of the Korean Triage Acuity Scale in Simulated Emergency Rooms Using Speech Recognition and Natural Language Processing: a Proof of Concept Study
CONCLUSION: We demonstrated the potential of an automatic KTAS classification system using speech recognition models, machine learning and BERT-based classifiers.PMID:34254471 | DOI:10.3346/jkms.2021.36.e175
Source: Journal of Korean Medical Science - July 13, 2021 Category: Biomedical Science Authors: Dongkyun Kim Jaehoon Oh Heeju Im Myeongseong Yoon Jiwoo Park Joohyun Lee Source Type: research

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

DEG/ENaC Ion Channels in the Function of the Nervous System: From Worm to Man
Adv Exp Med Biol. 2021;1349:165-192. doi: 10.1007/978-981-16-4254-8_9.ABSTRACTDEG/ENaC channels are voltage-independent Na+/Ca2+ channels that are conserved across species and are expressed in many different cell types and tissues, where they contribute to a wide array of physiological functions from transepithelial Na+ transport, to sensory perception, and learning and memory. In this chapter, we focus on the members of this family that are expressed in the nervous system, grouping them based on their function. Structurally, DEG/ENaC channels are trimers formed by either identical or homologous subunits, each one protrudi...
Source: Advances in Experimental Medicine and Biology - February 9, 2022 Category: Research Authors: Laura Bianchi Source Type: research

New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Documented Goals of Care Conversations with Hospitalized Patients After Severe Stroke (S513)
1. Understand the prevalence, frequency, timing, and content of a goals-of-care conversation (GOCC)2. Learn best practices in GOCC documentation
Source: Journal of Pain and Symptom Management - April 12, 2022 Category: Palliative Care Authors: Amber Comer, Claire Creutzfeldt, Robert Holloway, Stephanie Bartlett, James Slaven, Linda Williams, Alexia Torke Source Type: research

Documented Goals of Care Conversations with Hospitalized Patients After Severe Stroke (GP715)
1. Understand the prevalence, frequency, timing, and content of a goals-of-care conversation2. Learn best practices in goals-of-care conversation documentation
Source: Journal of Pain and Symptom Management - May 17, 2022 Category: Palliative Care Authors: Amber Comer, Claire Creutzfeldt, Lynn D'Cruz, Stephanie Bartlett, Robert Holloway, Alexia Torke, Laura Petras, Linda Williams Source Type: research

What Causes Sudden Vision Loss?
Discussion Vision loss, whether chronic or acute, is distressing at any time for patients and families. Prompt evaluation and treatment are important as maintenance of any acuity and light or movement is considered paramount. Most vision loss is due to chronic problems and aging issues but the differential diagnosis is broad. For any age, but especially children, uncorrected refractive errors can cause problems in not only in childhood but throughout someone’s lifetime. Visual impairment for distance vision is considered mild if worse than 6/12 in meters = 20/40 in feet or 0.3 LogMAR and for moderate impairment is 6/...
Source: PediatricEducation.org - September 5, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news